Barclays analyst Peter Lawson lowered the firm’s price target on Adaptimmune to $1 from $2 and keeps an Underweight rating on the shares post the Q2 report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ADAP: